A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

[1]  Thomas S. Lin,et al.  Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. , 2009, Blood.

[2]  G. Shapiro,et al.  Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. , 2008, Clinical lung cancer.

[3]  G. Schwartz,et al.  The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. , 2008, Cancer research.

[4]  C. Hudis,et al.  Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[5]  Thomas S. Lin,et al.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.

[6]  J. Stockman,et al.  Distinct Sets of Genetic Alterations in Melanoma , 2007 .

[7]  M. Piccart,et al.  A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Z. Hua.  Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .

[9]  R. Fonseca,et al.  Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points. , 2006, Haematologica.

[10]  P. Philip,et al.  A phase I study of flavopiridol and docetaxel , 2006, Investigational new drugs.

[11]  J. Sloan,et al.  Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points , 2005, Clinical Cancer Research.

[12]  R. Burger,et al.  A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. , 2005, Gynecologic oncology.

[13]  C. Cordon-Cardo,et al.  A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol , 2005, Clinical Cancer Research.

[14]  J. Verweij,et al.  Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Gönen.  A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials. , 2005, Contemporary clinical trials.

[16]  E. Eisenhauer,et al.  Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma , 2004, Investigational New Drugs.

[17]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[18]  G. Schwartz,et al.  Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. , 2003, Molecular cancer therapeutics.

[19]  M. Gonen,et al.  Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  G. Schwartz,et al.  Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Shah,et al.  Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[23]  G. Schwartz,et al.  Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[25]  S. Elledge,et al.  Cdk inhibitors in development and cancer. , 1996, Current opinion in genetics & development.

[26]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[27]  E. Sausville,et al.  Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.

[28]  R. Naik,et al.  An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum : isolation, structure and total synthesis , 1988 .